Cancers · 2025
Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Buzzatti Elisa, Paterno Giovangiacinto, Palmieri Raffaele, Esposito Fabiana, Cardillo Lucia, Taka Kristian, De Marchi Lucrezia, Zomparelli Marco, Zaganjori Kleda, Mallegni Flavia, Meddi Elisa, Moretti Federico, Cerroni Ilaria, Gurnari Carmelo, Maurillo Luca, Buccisano Francesco, Venditti Adriano, Del Principe Maria Ilaria
Аннотация
BACKGROUND: Acute myeloid leukemia (AML) necessitates timely treatment, yet the impact of prolonged time to treatment (TTT) on clinical outcomes remains debated, especially its impact on achieving measurable residual disease (MRD) negativity, a powerful prognostic indicator in AML.
METHODS: This retrospective study analyzed 196 adult AML patients treated with intensive chemotherapy, evaluating the effect of TTT on outcome measures and quality of response. TTT was categorized arbitrarily into <8, 8-14, and >14 days.
RESULTS: Results showed a median TTT of 11 days. Median overall survival (OS) was 414 days, with no significant differences among TTT groups (p = 0.48). Complete remission rate was 75.5%, with significantly higher rates in patients treated within 14 days (p = 0.004 and p = 0.006 for 8-14 and <8 days, respectively) compared to >14 days. MRD was assessed in 140 patients, with 35% achieving negativity, and no significant differences observed among TTT groups.
CONCLUSIONS: This study suggests that a treatment delay of up to 14 days does not negatively impact OS or MRD negativity. This timeframe potentially allows for thorough patient evaluation, including detailed genetic profiling and comorbidity assessment, facilitating a more personalized and optimized therapeutic strategy.
METHODS: This retrospective study analyzed 196 adult AML patients treated with intensive chemotherapy, evaluating the effect of TTT on outcome measures and quality of response. TTT was categorized arbitrarily into <8, 8-14, and >14 days.
RESULTS: Results showed a median TTT of 11 days. Median overall survival (OS) was 414 days, with no significant differences among TTT groups (p = 0.48). Complete remission rate was 75.5%, with significantly higher rates in patients treated within 14 days (p = 0.004 and p = 0.006 for 8-14 and <8 days, respectively) compared to >14 days. MRD was assessed in 140 patients, with 35% achieving negativity, and no significant differences observed among TTT groups.
CONCLUSIONS: This study suggests that a treatment delay of up to 14 days does not negatively impact OS or MRD negativity. This timeframe potentially allows for thorough patient evaluation, including detailed genetic profiling and comorbidity assessment, facilitating a more personalized and optimized therapeutic strategy.